Chapter 6. Management of Elevated Triglycerides and Non-High-Density Lipoprotein Cholesterol

  1. Peter P. Toth M.D., PH.D. Director of Preventive Cardiology Chief of Medicine Clinical Associate Professor1,2,3,4,
  2. Kevin C. Maki PH.D. President Chief Science Officer5

Published Online: 1 OCT 2008

DOI: 10.1002/9780470696873.ch6

Book Title

Practical Lipid Management: Concepts and Controversies

Practical Lipid Management: Concepts and Controversies

Additional Information

How to Cite

Toth, P. P. and Maki, K. C. (2008) Management of Elevated Triglycerides and Non-High-Density Lipoprotein Cholesterol , in Practical Lipid Management: Concepts and Controversies, John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9780470696873.ch6

Author Information

  1. 1

    Sterling Rock Falls Clinic, Ltd., USA

  2. 2

    CGH Medical Center Sterling, Illinois, USA

  3. 3

    Departments of Family and Community Medicine, University of Illinois College of Medicine Peoria, Illinois, USA

  4. 4

    Southern Illinois University School of Medicine, Springfield, Illinois, USA

  5. 5

    Provident Clinical Research & Consulting, Inc., Glen Ellyn, Illinois and Bloomington, Indiana, USA

Publication History

  1. Published Online: 1 OCT 2008
  2. Published Print: 17 OCT 2008

ISBN Information

Print ISBN: 9780470056905

Online ISBN: 9780470696873

SEARCH

CHAPTER TOOLS

Get PDF (230K)

Keywords:

  • elevated triglyceride management;
  • TG-rich lipoproteins and atherosclerosis and CHD;
  • TG-rich lipoprotein clearence impedance;
  • insulin resistance and hypertriglyceridemia;
  • lifestyle management;
  • VLDL-C lowering - fibrates, niacin, and omega-3 fatty acids;
  • diabetic dyslipidemia management;
  • fasting triglyceride level and low-density lipoprotein (LDL)

Summary

This chapter contains sections titled:

  • Clinical Factors Associated with Elevated TG and Non-HDL-C Levels

  • Disorders of TG-Rich Lipoprotein Clearance

  • Insulin Resistance and Hypertriglyceridemia

  • Excessive Production of VLDL: The Primary Lipid Abnormality in the Insulin-Resistant State

  • Reasons for Elevated Free Fatty Acid Levels in Insulin-Resistant States

  • Body Fat Distribution and Insulin Resistance

  • Insulin Resistance in the Nonobese Patient

  • Hypertriglyceridemia and the Development of Atherogenic Dyslipidemia

  • Lifestyle Management for the Metabolic Syndrome and Atherogenic Dyslipidemia

  • Drug Therapies

  • Intensification of Efforts to Lower LDL-C as a Means of Achieving the Non-HDL-C Goal

  • Targeting Triglyceride-Rich Lipoprotein Reduction as a Means of Achieving Non-HDL-C Goal

  • Fibrates

  • Niacin

  • Omega-3 Fatty Acids

  • Management of Diabetic Dyslipidemia

  • Controversy: Do we Need a Triglyceride Treatment Target to Insure a Predominance of Larger, More Buoyant LDL Particles?

Get PDF (230K)